Literature DB >> 9849615

The structure of human interferon-beta: implications for activity.

M Karpusas1, A Whitty, L Runkel, P Hochman.   

Abstract

Interferons (IFNs) are potent extracellular protein mediators of host defence and homoeostasis. This article reviews the structure of human IFN-beta (HuIFN-beta), in particular in relation to its activity. The recently determined crystal structure of HuIFN-beta provides a framework for understanding of the mechanism of differentiation of type I IFNs by their common receptor. Insights are generated by comparison with the structures of other type I IFNs and from the interpretation of existing mutagenesis data. The details of the observed carbohydrate structure, together with biochemical data, implicate the glycosylation of HuIFN-beta, which is uncommon among type I IFNs, as an important factor in the solubility, stability and, consequently, activity of the protein. Finally, these structural implications are discussed in the context of the clinical use of HuIFN-beta.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9849615     DOI: 10.1007/s000180050248

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  17 in total

Review 1.  Through the looking glass: the protein science of biosimilars.

Authors:  David Goldsmith; Martin Kuhlmann; Adrian Covic
Journal:  Clin Exp Nephrol       Date:  2007-09-28       Impact factor: 2.801

Review 2.  Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

3.  Rational development of a strategy for modifying the aggregatibility of proteins.

Authors:  Zhongping Tan; Shiying Shang; Samuel J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

4.  Insufficient (sub-native) helix content in soluble/solid aggregates of recombinant and engineered forms of IL-2 throws light on how aggregated IL-2 is biologically active.

Authors:  Uzma Fatima; Balvinder Singh; Karthikeyan Subramanian; Purnananda Guptasarma
Journal:  Protein J       Date:  2012-10       Impact factor: 2.371

Review 5.  Effects of localized interactions and surface properties on stability of protein-based therapeutics.

Authors:  Brittney J Mills; Jennifer S Laurence Chadwick
Journal:  J Pharm Pharmacol       Date:  2016-11-10       Impact factor: 3.765

6.  Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice.

Authors:  Miranda M C van Beers; Melody Sauerborn; Francesca Gilli; Vera Brinks; Huub Schellekens; Wim Jiskoot
Journal:  Pharm Res       Date:  2011-05-05       Impact factor: 4.200

7.  Aggregated recombinant human interferon Beta induces antibodies but no memory in immune-tolerant transgenic mice.

Authors:  Miranda M C van Beers; Melody Sauerborn; Francesca Gilli; Vera Brinks; Huub Schellekens; Wim Jiskoot
Journal:  Pharm Res       Date:  2010-05-25       Impact factor: 4.200

Review 8.  Effects of glycosylation on the stability of protein pharmaceuticals.

Authors:  Ricardo J Solá; Kai Griebenow
Journal:  J Pharm Sci       Date:  2009-04       Impact factor: 3.534

9.  Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer.

Authors:  Elena Chertova; Cristina Bergamaschi; Oleg Chertov; Raymond Sowder; Jenifer Bear; James D Roser; Rachel K Beach; Jeffrey D Lifson; Barbara K Felber; George N Pavlakis
Journal:  J Biol Chem       Date:  2013-05-06       Impact factor: 5.157

10.  Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β.

Authors:  Meenu Wadhwa; Meena Subramanyam; Susan Goelz; Jaya Goyal; Vijay Jethwa; Wendy Jones; James G Files; Daniel Kramer; Chris Bird; Paula Dilger; Michael Tovey; Christophe Lallemand; Robin Thorpe
Journal:  J Interferon Cytokine Res       Date:  2013-07-13       Impact factor: 2.607

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.